GHRP-2

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide and one of the first generation of growth hormone secretagogues developed for research into GH deficiency and metabolic disorders. Structurally, it functions as a ghrelin mimetic - binding to and activating the GHS-R1a (growth hormone secretagogue receptor type 1a) in the anterior pituitary and hypothalamus to trigger pulsatile GH release.

Developed in the 1980s and 1990s alongside GHRP-6, GHRP-2 was specifically engineered to retain the potent GH-releasing activity of its predecessor while reducing some of the less desirable properties such as prolactin and cortisol elevation. The result is a peptide that produces robust, reproducible GH pulses while maintaining a cleaner side effect profile for extended research use.

The mechanism of GHRP-2 involves dual action: direct stimulation of somatotroph cells in the pituitary to release stored GH, and indirect hypothalamic action that suppresses somatostatin (the GH inhibitory hormone) while potentiating GHRH signalling. This dual mechanism explains why combining GHRP-2 with a GHRH analogue produces a synergistic rather than merely additive response - each peptide removes a different brake on GH secretion.

In terms of potency, GHRP-2 is generally considered the most potent of the first-generation GHRP peptides, capable of elevating serum GH to 7-15 times baseline in research subjects. Peak GH levels occur approximately 15-30 minutes post-injection and return to baseline within 3-4 hours. The half-life of approximately 15-30 minutes necessitates multiple daily injections for sustained GH elevation.

Research into GHRP-2 has extended beyond simple GH secretion. Studies have documented direct organ-protective effects that appear to be partially independent of GH elevation - including hepatoprotective properties in models of liver injury, cardioprotective effects mediated through myocardial GHS-R1a receptors, and neuroprotective activity. These pleiotropic effects make GHRP-2 an interesting research tool beyond simple GH replacement protocols.

The ghrelin-mimetic activity of GHRP-2 produces a characteristic hunger spike approximately 20-30 minutes post-injection. While less intense than the appetite stimulation produced by GHRP-6, this effect has been studied in the context of cachexia research and models of appetite dysregulation. Researchers studying energy balance and feeding behaviour find this property particularly relevant.

GHRP-2 is most commonly used in research as part of a combination protocol with CJC-1295 (a long-acting GHRH analogue). This combination produces dramatically elevated and sustained GH levels compared to either peptide alone, and has become one of the most commonly studied GH-optimisation protocols in the research peptide field.